Black Diamond Therapeutics Q1 2026 net loss $9.0M; cash $118.3M; GBM trial dosed first patient

Black Diamond Therapeutics, Inc.

2026-Q1 EPS reported -$0.16

Net loss of $9.0M vs net income of $56.5M in Q1 2025 (prior year included license revenue).
Cash, cash equivalents, and investments $118.3M as of March 31, 2026; sufficient into 2H 2028.
R&D expenses $7.0M (down from $10.5M); G&A expenses $4.3M (down from $5.0M).
First patient dosed in Phase 2 trial of silevertinib + temozolomide for newly diagnosed EGFRvIII+ GBM.
Oral presentation of silevertinib Phase 2 frontline NSCLC data at ASCO 2026 on May 30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $9.0 million.

Period: first quarter ended March 31, 2026
Net income: $9.0 million
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $9.0 million, as compared to net income of $56.5 million for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-26-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.